These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 24007628)

  • 21. [Detection of epidermal growth factor receptor gene mutations in non-small cell lung cancer using bi-loop probe specific primer quantitative PCR].
    Wang LS; Zhang Y; Lu XJ; Lu HJ; Zhou L; Wang YS; Deng L; Huang MJ; Peng F; Wang J; Ren L; Hou M; Li L; Xu Y; Ying BW; Lu Y
    Zhonghua Bing Li Xue Za Zhi; 2011 Oct; 40(10):667-70. PubMed ID: 22321544
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The peptide nucleic acid-locked nucleic acid polymerase chain reaction clamp-based test for epidermal growth factor receptor mutations in bronchoscopic cytological specimens of non-small cell lung cancer.
    Yamada N; Oizumi S; Asahina H; Shinagawa N; Kikuchi E; Kikuchi J; Sakakibara-Konishi J; Tanaka T; Kobayashi K; Hagiwara K; Nishimura M
    Oncology; 2012; 82(6):341-6. PubMed ID: 22677909
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Detection of the T790M mutation of EGFR in plasma of advanced non-small cell lung cancer patients with acquired resistance to tyrosine kinase inhibitors (West Japan oncology group 8014LTR study).
    Takahama T; Sakai K; Takeda M; Azuma K; Hida T; Hirabayashi M; Oguri T; Tanaka H; Ebi N; Sawa T; Bessho A; Tachihara M; Akamatsu H; Bandoh S; Himeji D; Ohira T; Shimokawa M; Nakanishi Y; Nakagawa K; Nishio K
    Oncotarget; 2016 Sep; 7(36):58492-58499. PubMed ID: 27542267
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Detection of epidermal growth factor receptor mutation in non-small-cell lung carcinoma using cytological and histological specimens.
    Xu H; Sun W; Zhang G; Cheng Y
    J BUON; 2015; 20(1):142-5. PubMed ID: 25778309
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Outcomes of an Australian testing programme for epidermal growth factor receptor mutations in non-small cell lung cancer.
    Peters MJ; Bowden JJ; Carpenter P; Lewis J; Solomon B
    Intern Med J; 2014 Jun; 44(6):575-80. PubMed ID: 24720523
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment outcome comparisons between exons 19 and 21 EGFR mutations for non-small-cell lung cancer patients with malignant pleural effusion after first-line and second-line tyrosine kinase inhibitors.
    Zheng Z; Xie D; Su H; Lin B; Zhao L; Deng X; Chen H; Fei S; Jin X; Xie C
    Tumour Biol; 2017 Jun; 39(6):1010428317706211. PubMed ID: 28618947
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of non-small-cell lung cancer with activating EGFR mutations in malignant effusion and cerebrospinal fluid: rapid and sensitive detection of exon 19 deletion E746-A750 and exon 21 L858R mutation by immunocytochemistry.
    Kawahara A; Azuma K; Sumi A; Taira T; Nakashima K; Aikawa E; Abe H; Yamaguchi T; Takamori S; Akiba J; Kage M
    Lung Cancer; 2011 Oct; 74(1):35-40. PubMed ID: 21444121
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Plasma epidermal growth factor receptor mutation testing with a chip-based digital PCR system in patients with advanced non-small cell lung cancer.
    Kasahara N; Kenmotsu H; Serizawa M; Umehara R; Ono A; Hisamatsu Y; Wakuda K; Omori S; Nakashima K; Taira T; Naito T; Murakami H; Koh Y; Mori K; Endo M; Nakajima T; Yamada M; Kusuhara M; Takahashi T
    Lung Cancer; 2017 Apr; 106():138-144. PubMed ID: 28285688
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Assessment of high-sensitive methods for the detection of EGFR mutations in circulating free tumor DNA from NSCLC patients.
    Pasquale R; Fenizia F; Esposito Abate R; Sacco A; Esposito C; Forgione L; Rachiglio AM; Bevilacqua S; Montanino A; Franco R; Rocco G; Botti G; Denis MG; Morabito A; De Luca A; Normanno N
    Pharmacogenomics; 2015; 16(10):1135-48. PubMed ID: 26249748
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of plasma and tissue samples in epidermal growth factor receptor mutation by ARMS in advanced non-small cell lung cancer.
    Ma M; Shi C; Qian J; Teng J; Zhong H; Han B
    Gene; 2016 Oct; 591(1):58-64. PubMed ID: 27370697
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Usefulness of EGFR mutation screening in pleural fluid to predict the clinical outcome of gefitinib treated patients with lung cancer.
    Soh J; Toyooka S; Aoe K; Asano H; Ichihara S; Katayama H; Hiraki A; Kiura K; Aoe M; Sano Y; Sugi K; Shimizu N; Date H
    Int J Cancer; 2006 Nov; 119(10):2353-8. PubMed ID: 16921488
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Detection of epidermal growth factor receptor mutations in non-small-cell lung carcinoma by direct sequencing and correlations with clinicopathological characteristics and sample types].
    Sun MH; Yang F; Shen L; Zhang L; Chen Y; Cai X; Zhu XL; Zhou XY
    Zhonghua Bing Li Xue Za Zhi; 2011 Oct; 40(10):655-9. PubMed ID: 22321541
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Circulating plasma microRNAs as potential markers to identify EGFR mutation status and to monitor epidermal growth factor receptor-tyrosine kinase inhibitor treatment in patients with advanced non-small cell lung cancer.
    Qu L; Li L; Zheng X; Fu H; Tang C; Qin H; Li X; Wang H; Li J; Wang W; Yang S; Wang L; Zhao G; Lv P; Lei Y; Zhang M; Gao H; Song S; Liu X
    Oncotarget; 2017 Jul; 8(28):45807-45824. PubMed ID: 28496005
    [TBL] [Abstract][Full Text] [Related]  

  • 34. EGFR mutation status in primary lung adenocarcinomas and corresponding metastatic lesions: discordance in pleural metastases.
    Han HS; Eom DW; Kim JH; Kim KH; Shin HM; An JY; Lee KM; Choe KH; Lee KH; Kim ST; Koo JH; Lee HC; Lee OJ
    Clin Lung Cancer; 2011 Nov; 12(6):380-6. PubMed ID: 21729655
    [TBL] [Abstract][Full Text] [Related]  

  • 35. EGFR mutations in squamous cell lung cancer in never-smokers.
    Baik CS; Pritchard CC; Eaton KD; Chow LQ
    J Thorac Oncol; 2013 Jan; 8(1):e6-7. PubMed ID: 23242446
    [No Abstract]   [Full Text] [Related]  

  • 36. Direct sequencing and amplification refractory mutation system for epidermal growth factor receptor mutations in patients with non-small cell lung cancer.
    Chu H; Zhong C; Xue G; Liang X; Wang J; Liu Y; Zhao S; Zhou Q; Bi J
    Oncol Rep; 2013 Nov; 30(5):2311-5. PubMed ID: 24002698
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PNA clamping-assisted fluorescence melting curve analysis for detecting EGFR and KRAS mutations in the circulating tumor DNA of patients with advanced non-small cell lung cancer.
    Han JY; Choi JJ; Kim JY; Han YL; Lee GK
    BMC Cancer; 2016 Aug; 16():627. PubMed ID: 27519791
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Epidermal growth factor receptor mutation status in circulating free DNA in serum: from IPASS, a phase III study of gefitinib or carboplatin/paclitaxel in non-small cell lung cancer.
    Goto K; Ichinose Y; Ohe Y; Yamamoto N; Negoro S; Nishio K; Itoh Y; Jiang H; Duffield E; McCormack R; Saijo N; Mok T; Fukuoka M
    J Thorac Oncol; 2012 Jan; 7(1):115-21. PubMed ID: 21900837
    [TBL] [Abstract][Full Text] [Related]  

  • 39. EGFR-L858R mutant enhances lung adenocarcinoma cell invasive ability and promotes malignant pleural effusion formation through activation of the CXCL12-CXCR4 pathway.
    Tsai MF; Chang TH; Wu SG; Yang HY; Hsu YC; Yang PC; Shih JY
    Sci Rep; 2015 Sep; 5():13574. PubMed ID: 26338423
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer.
    Kimura H; Kasahara K; Kawaishi M; Kunitoh H; Tamura T; Holloway B; Nishio K
    Clin Cancer Res; 2006 Jul; 12(13):3915-21. PubMed ID: 16818687
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.